| 000 | 01530 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250514235200.0 | ||
| 264 | 0 | _c20050901 | |
| 008 | 200509s 0 0 eng d | ||
| 022 | _a0009-9236 | ||
| 024 | 7 |
_a10.1016/j.clpt.2005.04.013 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKang, Eun Seok | |
| 245 | 0 | 0 |
_aEffects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _cAug 2005 |
||
| 300 |
_a202-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xpharmacology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPPAR gamma _xdrug effects |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 | _aRosiglitazone |
| 650 | 0 | 4 |
_aThiazolidinediones _xpharmacology |
| 700 | 1 | _aPark, So Young | |
| 700 | 1 | _aKim, Hyeong Jin | |
| 700 | 1 | _aKim, Chul Sik | |
| 700 | 1 | _aAhn, Chul Woo | |
| 700 | 1 | _aCha, Bong Soo | |
| 700 | 1 | _aLim, Sung Kil | |
| 700 | 1 | _aNam, Chung Mo | |
| 700 | 1 | _aLee, Hyun Chul | |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 78 _gno. 2 _gp. 202-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.clpt.2005.04.013 _zAvailable from publisher's website |
| 999 |
_c15723329 _d15723329 |
||